Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis Bullosa.

The financing supports Eliksa's clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with ...

Four day conference for Epidermolysis Bullosa patients and medical experts Online, June 15, 2010 (Newswire.com) - (June 15, 2010) - A family is getting excited and preparing to pack for a four day ...

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis bullosa (EB), today launches a call for Basic Science ...

BOSTON--(BUSINESS WIRE)--BPGbio Inc (BPG), an AI-powered biopharma with a mission to reimagine biology for humanity, announced today that the company has reached a partnership agreement with ...

Research into new bandaging aims to ease the agony experienced by those living with genetic skin condition Epidermolysis Bullosa (EB), commonly referred to as 'butterfly skin'. Scientists at Maynooth ...

EB charity Debra Ireland has launched an appeal this Christmas to raise funds for extra supports, including home nursing hours, for 300 families in Ireland with children suffering from this genetic ...

An Irish engineer who climbed Mount Kilimanjaro in honor of his late brother now plans to row the Irish Sea to raise awareness about the rare disease that he died of, epidermolysis bullosa (EB).

BOSTON, Nov. 27, 2018 /PRNewswire/ -- Constant Pharmaceuticals today announced that it plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, ...

DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for EB, a rare and life-limiting genetic condition. As the research arm of DEBRA Austria – a patient ...